International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051) (RHYTHM-AF)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Atrial Fibrillation

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT01119716

2010_025

6621-051

Details and patient eligibility

About

This study will create a prospective registry of consecutive patients with Atrial Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of Afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.

Enrollment: 4,658 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant with documented atrial fibrillation (confirmed by electrocardiogram) in the hospital setting at the time of enrollment
• Planned cardioversion (of atrial fibrillation)

Exclusion criteria

• Already enrolled in this or any other clinical trial
• Atrial flutter

Trial design

4,658 participants in 1 patient group

All Enrolled Participants

Description:

Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options